Connecting underrepresented populations to clinical trials at Ohio State University
The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) Project
NA · Ohio State University Comprehensive Cancer Center · NCT06314672
This study is trying to find better ways to connect racial and ethnic minorities to cancer clinical trials at Ohio State University to help them participate more.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 208 (estimated) |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center (other) |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT06314672 on ClinicalTrials.gov |
What this trial studies
This project aims to improve the referral and enrollment of racial and ethnic minorities in clinical trials for cancer treatment and prevention. It involves a multi-phase approach, starting with a baseline assessment of current referral patterns and barriers to participation. Following this, a multi-level intervention will be implemented across ten counties to enhance accrual to clinical trials. The effectiveness of these interventions will be evaluated to determine their impact on increasing minority participation in clinical trials.
Who should consider this trial
Good fit: Ideal candidates include racial and ethnic minorities residing in the Ohio State University Comprehensive Cancer Center catchment area.
Not a fit: Patients who are not part of racial or ethnic minority groups may not receive direct benefits from this study.
Why it matters
Potential benefit: If successful, this project could significantly increase access to clinical trials for underrepresented populations, leading to better cancer treatment outcomes.
How similar studies have performed: Other studies have shown success in increasing minority participation in clinical trials through targeted outreach and education efforts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Phase I: 9 counties in the OSUCCC catchment area * Phase II: Patients, providers, and hospital systems/referral centers that directly addresses challenges identified in Phase I * Phase II: The project will involve the OSUCCC, the OSU James Cancer Network sites and the Columbus and Dayton NCORP sites
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Electra D Paskett, PhD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm